Navigation Links
Solos Endoscopy Finishes the 3rd Quarter Strong
Date:10/21/2011

BOSTON, Oct. 21, 2011 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) announced today that the Company finished the 3rd Quarter strong with sales revenues during the three months ended September 30, 2011 in the amount of $86,717.40.  The revenue for the third quarter is a result of instrument sales to over sixty Hospitals, Clinics, Healthcare Centers, Medical Centers and Surgery Centers across the United States.

Solos Breast Endoscopy component sales accounted for approximately 39.5% of the total sales revenue for the third quarter or $34,290. The MammoView® instrument line, designed exclusively for breast endoscopy, has become crucial to early breast cancer screening as a method to significantly reduce breast cancer death rates. The Solos MammoView® Breast Endoscopy System is designed to distinguish and inspect suspicious pre-cancerous lesions that are undetectable by other methods as well as complement existing diagnosis and treatment options with direct endoscopic observation.

"We're proud of our efforts during the 3rd Quarter, and we anticipate continued sales growth as we finish out the year," stated Bob Segersten, President of Solos Endoscopy, Inc.

The Company recently announced its intentions to donate 5% of its sales from the MammoView® Breast Endoscopy Instrument line for the month of October to support breast cancer awareness through education and early detection. The Company expects to post its full unaudited financial results for the quarter ended September 30, 2011 on the OTC Markets Group website within in the next thirty days.

About Solos Endoscopy, Inc.:Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.CONTACT:

Amanda Segerstenrsegersten@solosendoscopy.com
'/>"/>

SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solos Endoscopy to Support National Breast Cancer Foundation With Sales of Its MammoView® Breast Endoscopy Components to US Hospitals
2. Solos Endoscopy to Market its MammoView® Breast Endoscopy Components to US Hospitals
3. Solos Endoscopy Reports 32% Increase in Breast Endoscopy Sales
4. Solos Endoscopy to Reduce Debt by Over $620,000
5. Solos Endoscopys MammoView® System Proves Crucial to Early Breast Cancer Detection
6. Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction
7. Solos Endoscopy, Inc. To Launch New Corporate Website
8. Solos Endoscopy, Inc. Strengthens Current Line of Laparoscopic Instruments
9. Solos Endoscopy, Inc. To Introduce New Urology Instrument Line
10. Solos Endoscopy, Inc. Reports $34,291 in Sales Revenue for January 2011
11. Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... The Rebound mobile app is poised to become a vital ... prescription drug addiction. The app empowers users to develop an ... their dosage in a safe, controlled manner while maximizing well-being. ... 100,000 people to sign up will enjoy 3 months of ... ...
(Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
(Date:9/25/2017)... 2017  EpiVax, Inc., a leader in the ... today announced the launch of EpiVax Oncology Inc., ... therapeutic cancer vaccines. EpiVax has provided $500,000 in ... enabling technologies to the new precision immunotherapy venture. ... Oncology as Chief Executive Officer. Gad brings over ...
Breaking Medicine Technology:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... has recently contributed a medical article to the newly revamped Cosmetic Town ... article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Leading pediatric ... peers in Washington, D.C., for the 49th Congress of the International Society of ... Vice President of the Center for Cancer and Blood Disorders at Children’s ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and ... 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will ... Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... $3,296 in property taxes a year. In some states—like New York, New Jersey, ... By contrast, many overseas retirement havens have extremely low property-tax rates, which contributes ...
Breaking Medicine News(10 mins):